TG Therapeutics Inc. (NASDAQ:TGTX) – Investment analysts at FBR & Co dropped their FY2018 earnings per share (EPS) estimates for TG Therapeutics in a research note issued to investors on Wednesday. FBR & Co analyst E. White now forecasts that the firm will post earnings per share of ($1.63) for the year, down from their prior estimate of ($1.60). FBR & Co currently has a “Buy” rating on the stock.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.19. TG Therapeutics had a negative net margin of 47,494.08% and a negative return on equity of 83.18%.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The legal version of this story can be viewed at http://www.dailypolitical.com/2016/11/29/tg-therapeutics-inc-tgtx-to-post-fy2018-earnings-of-1-63-per-share-fbr-co-forecasts.html.

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

A number of other research analysts have also weighed in on TGTX. Ladenburg Thalmann restated a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a research report on Saturday, October 15th. Roth Capital set a $33.00 price objective on TG Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 20th. HC Wainwright restated a “buy” rating and set a $18.00 price objective (down previously from $22.00) on shares of TG Therapeutics in a research report on Saturday, October 15th. Zacks Investment Research lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 10th. Finally, S&P Equity Research cut their price objective on TG Therapeutics from $7.15 to $6.40 in a research report on Wednesday, August 24th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $20.86.

TG Therapeutics (NASDAQ:TGTX) traded down 2.61% on Monday, reaching $5.60. The company’s stock had a trading volume of 614,646 shares. TG Therapeutics has a one year low of $4.90 and a one year high of $14.87. The company’s market capitalization is $306.49 million. The firm has a 50-day moving average of $6.05 and a 200-day moving average of $6.60.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The legal version of this story can be viewed at http://www.dailypolitical.com/2016/11/29/tg-therapeutics-inc-tgtx-to-post-fy2018-earnings-of-1-63-per-share-fbr-co-forecasts.html.

A number of hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its stake in shares of TG Therapeutics by 0.5% in the third quarter. Rhumbline Advisers now owns 37,737 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 190 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of TG Therapeutics by 0.6% in the third quarter. California State Teachers Retirement System now owns 77,735 shares of the biopharmaceutical company’s stock valued at $602,000 after buying an additional 500 shares during the last quarter. BlackRock Group LTD increased its stake in TG Therapeutics by 2.9% in the third quarter. BlackRock Group LTD now owns 17,779 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 504 shares in the last quarter. Mariner Wealth Advisors LLC increased its stake in TG Therapeutics by 4.4% in the second quarter. Mariner Wealth Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 800 shares in the last quarter. Finally, BlackRock Advisors LLC increased its stake in TG Therapeutics by 8.5% in the third quarter. BlackRock Advisors LLC now owns 19,680 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 1,549 shares in the last quarter. 49.50% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

5 Day Chart for NASDAQ:TGTX

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.